FRA:ILU - Deutsche Boerse Ag - US4523271090 - Common Stock - Currency: EUR
FRA:ILU (4/22/2025, 7:00:00 PM)
64.75
-0.53 (-0.81%)
The current stock price of ILU.DE is 64.75 EUR. In the past month the price decreased by -20.32%. In the past year, price decreased by -42.99%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
TN8.DE | THERMO FISHER SCIENTIFIC INC | 19.65 | 142.73B | ||
DAP.DE | DANAHER CORP | 25.97 | 122.43B | ||
DIM.PA | SARTORIUS STEDIM BIOTECH | 51.18 | 18.93B | ||
56S1.DE | SARTORIUS STEDIM BIOTECH | 49.38 | 18.26B | ||
SRT3.DE | SARTORIUS AG-VORZUG | 51.62 | 16.50B | ||
SRT.DE | SARTORIUS AG | 42.48 | 13.58B | ||
ERF.PA | EUROFINS SCIENTIFIC | 27.42 | 8.99B | ||
ESF0.DE | EUROFINS SCIENTIFIC | 27.23 | 8.93B | ||
QIA.DE | QIAGEN N.V. | 19.02 | 7.97B | ||
1SXP.DE | SCHOTT PHARMA AG& CO KGAA | 26.52 | 3.55B | ||
EVT.DE | EVOTEC SE | N/A | 2.43B | ||
GXI.DE | GERRESHEIMER AG | 11.14 | 1.80B |
Illumina, Inc. engages in the development, manufacturing, and marketing of life science tools and integrated systems for large-scale analysis of genetic variation and function. The company is headquartered in San Diego, California and currently employs 8,970 full-time employees. The company went IPO on 2000-06-28. Its products and services serve customers in a range of markets, enabling the adoption of genomic solutions in research and clinical settings. Its DNA sequencing technology is based on its reversible terminator-based sequencing chemistry, referred to as sequencing by synthesis biochemistry. Its BeadArray technology combines microscopic beads and a substrate in a manufacturing process to produce arrays that can perform many assays simultaneously. Its sequencing applications include whole-genome sequencing kits, which sequence entire genomes of any size and complexity, and targeted resequencing kits, which can sequence exomes, specific genes, RNA or other genomic regions of interest. Its customers include genomic research centers, academic institutions, government laboratories, hospitals, pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and others.
ILLUMINA INC
5200 Illumina Way
San Diego CALIFORNIA US
Employees: 8970
Company Website: https://www.illumina.com
Investor Relations: https://investor.illumina.com
Phone: 18582024500
The current stock price of ILU.DE is 64.75 EUR. The price decreased by -0.81% in the last trading session.
The exchange symbol of ILLUMINA INC is ILU and it is listed on the Deutsche Boerse Ag exchange.
ILU.DE stock is listed on the Deutsche Boerse Ag exchange.
31 analysts have analysed ILU.DE and the average price target is 121.13 EUR. This implies a price increase of 87.07% is expected in the next year compared to the current price of 64.75. Check the ILLUMINA INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
ILLUMINA INC (ILU.DE) has a market capitalization of 10.25B EUR. This makes ILU.DE a Large Cap stock.
ILLUMINA INC (ILU.DE) currently has 8970 employees.
ILLUMINA INC (ILU.DE) has a resistance level at 66.4. Check the full technical report for a detailed analysis of ILU.DE support and resistance levels.
The Revenue of ILLUMINA INC (ILU.DE) is expected to decline by -0.75% in the next year. Check the estimates tab for more information on the ILU.DE EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
ILU.DE does not pay a dividend.
ILLUMINA INC (ILU.DE) will report earnings on 2025-05-08, after the market close.
The PE ratio for ILLUMINA INC (ILU.DE) is 29.98. This is based on the reported non-GAAP earnings per share of 2.16 and the current share price of 64.75 EUR. Check the full fundamental report for a full analysis of the valuation metrics for ILU.DE.
ChartMill assigns a fundamental rating of 4 / 10 to ILU.DE. Both the profitability and the financial health of ILU.DE get a neutral evaluation. Nothing too spectacular is happening here.
Over the last trailing twelve months ILU.DE reported a non-GAAP Earnings per Share(EPS) of 2.16. The EPS increased by 181.61% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -19.39% | ||
ROE | -51.5% | ||
Debt/Equity | 0.63 |
ChartMill assigns a Buy % Consensus number of 74% to ILU.DE. The Buy consensus is the average rating of analysts ratings from 31 analysts.
For the next year, analysts expect an EPS growth of 85.5% and a revenue growth -0.75% for ILU.DE